Nolan R Vale
Overview
Explore the profile of Nolan R Vale including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levin N, Kim S, Marquardt C, Vale N, Yu Z, Sindiri S, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38816232
Background: Tumor-infiltrating lymphocytes (TILs) targeting neoantigens can effectively treat a selected set of metastatic solid cancers. However, harnessing TILs for cancer treatments remains challenging because neoantigen-reactive T cells are often...
2.
Yossef R, Krishna S, Sindiri S, Lowery F, Copeland A, Gartner J, et al.
Cancer Cell
. 2023 Dec;
41(12):2154-2165.e5.
PMID: 38039963
Circulating T cells from peripheral blood (PBL) can provide a rich and noninvasive source for antitumor T cells. By single-cell transcriptomic profiling of 36 neoantigen-specific T cell clones from 6...
3.
Kim S, Vale N, Zacharakis N, Krishna S, Yu Z, Gasmi B, et al.
Cancer Immunol Res
. 2022 Jun;
10(8):932-946.
PMID: 35749374
Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most neoantigens arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of...
4.
Lowery F, Krishna S, Yossef R, Parikh N, Chatani P, Zacharakis N, et al.
Science
. 2022 Feb;
375(6583):877-884.
PMID: 35113651
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen-specific TCR clonotypes (NeoTCRs) from 10 metastatic...
5.
Levin N, Paria B, Vale N, Yossef R, Lowery F, Parkhurst M, et al.
Clin Cancer Res
. 2021 Jun;
27(18):5084-5095.
PMID: 34168045
Purpose: Immunotherapies mediate the regression of human tumors through recognition of tumor antigens by immune cells that trigger an immune response. Mutations in the oncogenes occur in about 30% of...